buprenorphine hydrochloride

FDA Drug Profile — buprenorphine hydrochloride, BELBUCA

Drug Details

Generic Name
buprenorphine hydrochloride
Brand Names
buprenorphine hydrochloride, BELBUCA
Application Number
ANDA090622
Sponsor
PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma
NDC Codes
14
Dosage Forms
TABLET, FILM, SOLUBLE
Routes
SUBLINGUAL, BUCCAL
Active Ingredients
BUPRENORPHINE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Buprenorphine and Naloxone Sublingual Tablets are indicated for the maintenance treatment of opioid dependence. Buprenorphine and Naloxone Sublingual Tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. Buprenorphine and Naloxone Sublingual Tablets contain buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist, and are indicated for the maintenance treatment of opioid dependence. ( ) Buprenorphine and Naloxone Sublingual Tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( )